<DOC>
	<DOCNO>NCT02159365</DOCNO>
	<brief_summary>To explore whether Elotuzumab dose administration approximately 60 minute feasible safe .</brief_summary>
	<brief_title>Study Safety Elotuzumab Administered Over Approximately 60 Minutes Combination With Lenalidomide Dexamethasone Newly Diagnosed Relapsed/Refractory Multiple Myeloma Patients</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>For information regard BMS clinical trial participation , please visit www.BMSStudyConnect.com Eastern Cooperative Oncology Group ( ECOG ) performance status ≤2 Documented evidence active multiple myeloma : Newly diagnose , candidate transplant Relapsed/refractory receive 3 prior line therapy Prior Lenalidomide exposure permit follow criterion fulfil : Not refractory prior Lenalidomide define progression receive Lenalidomide within 60 day last dose Lenalidomide Subject discontinue Lenalidomide due Grade ≥3 related adverse event ( AE ) Target Disease Exceptions Plasma cell leukemia Monoclonal gammopathy undetermined significance ( MGUS ) Smoldering Myeloma Primary amyloidosis Polyneuropathy , organomegaly , endocrinopathy , monoclonal gammopathy , skin change ( POEMS ) syndrome</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>